Quick Take

The FDA issued a formal warning letter to Aerosol and Liquid Packaging, Inc. on July 24, 2024, citing significant Current Good Manufacturing Practice (CGMP) violations. The regulatory action classifies the company's finished pharmaceutical products as adulterated due to failures in maintaining the quality and safety standards required for drug production.

Why It Matters

This warning is part of an intensified period of FDA oversight regarding contract manufacturers of over-the-counter (OTC) ophthalmic and liquid health products. For eye care professionals, these citations are a red flag for potential sterility and contamination risks that could lead to serious ocular infections for patients. Because many of these manufacturers produce white-label or generic products for various brands, such violations often signal the need for clinicians to scrutinize the supply chain of the OTC drops they recommend.

Key Details

• FDA Warning Letter 676746 identifies systemic failures to comply with Current Good Manufacturing Practice (CGMP) regulations.
• The inspection findings led the FDA to designate the facility's finished pharmaceuticals as adulterated under the Federal Food, Drug, and Cosmetic Act.
• The violations specifically concern the manufacturer's inability to ensure the identity, strength, quality, and purity of their drug products.
• The notice follows a trend of increased regulatory scrutiny on liquid pharmaceutical manufacturing facilities following high-profile contamination incidents in the eye care sector.

Practice Implications

Clinicians should remain vigilant about the brands of OTC eye drops and lid hygiene products their patients are using, as contract manufacturers like Aerosol and Liquid Packaging often produce goods for multiple labels. If patients present with unexplained ocular surface inflammation or infection while using generic OTC products, providers should consider the possibility of manufacturing-related contamination and report adverse events to the FDA’s MedWatch program.

Who's Affected

What's Next

The manufacturer is required to respond to the FDA within 15 working days with a detailed plan for corrective actions. Failure to remediate these CGMP violations could result in further legal action, including product seizures, injunctions, or a complete cessation of manufacturing operations.